Neurocrine Biosciences (NBIX) Enterprise Value (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Enterprise Value of -$389.8 million for Q2 2026, up 60.05% year-over-year from -$243.6 million in Q2 2025, and up 70.38% on a QoQ basis from -$1.3 billion in Q1 2026.
Neurocrine Biosciences (NBIX) Enterprise Value (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Enterprise Value for 17 years, with the latest figure at -$389.8 million in Q2 2026.
- Enterprise Value for Q2 2026 came in at -$389.8 million, up 60.05% year-over-year; the trailing twelve-month figure through Jun 2026 was -$389.8 million (up 60.05% YoY), and the FY2025 annual result was -$1.5 billion, down 37.57% from the prior year.
- Enterprise Value rose to -$389.8 million in Q2 2026, from -$1.3 billion in the prior quarter.
- Over five years, Enterprise Value peaked at -$389.8 million in Q2 2026 and troughed at -$1.5 billion in Q4 2025.
- A 5-year average of -$993.9 million and a median of -$1.0 billion in 2022 frame the typical range for Enterprise Value.
- The widest annual swing landed in 2023, when Enterprise Value sank 50.66%; it then soared 60.05% in 2026.
- A 5-year view of Enterprise Value shows it stood at -$997.1 million in 2022, then dropped by 4.26% to -$1.0 billion in 2023, then retreated by 3.51% to -$1.1 billion in 2024, then tumbled by 37.57% to -$1.5 billion in 2025, then soared by 73.67% to -$389.8 million in 2026.
- Per Business Quant data, the three most recent Enterprise Value figures were -$389.8 million in Q2 2026, -$1.3 billion in Q1 2026, and -$1.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | -882.82 Mn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | -3.65 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -5.79 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | -2.66 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | -886.50 Mn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | -389.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | -164.00 Mn |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | -656.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -389.80 Mn |
| Mar 31, 2026 | -1.32 Bn |
| Dec 31, 2025 | -1.48 Bn |
| Sep 30, 2025 | -1.11 Bn |
| Jun 30, 2025 | -975.60 Mn |
| Mar 31, 2025 | -943.50 Mn |
| Dec 31, 2024 | -1.08 Bn |
| Sep 30, 2024 | -1.23 Bn |
| Jun 30, 2024 | -1.04 Bn |
| Mar 31, 2024 | -1.21 Bn |
| Dec 31, 2023 | -1.04 Bn |
| Sep 30, 2023 | -1.10 Bn |
| Jun 30, 2023 | -976.70 Mn |
| Mar 31, 2023 | -894.60 Mn |
| Dec 31, 2022 | -997.10 Mn |
| Sep 30, 2022 | -799.40 Mn |
| Jun 30, 2022 | -648.30 Mn |
| Mar 31, 2022 | -664.90 Mn |
| Dec 31, 2021 | -714.50 Mn |
| Sep 30, 2021 | -765.90 Mn |